LEADER 03278nam  22005895  450 
001 9910349443803321
005 20210421192125.0
010   $a3-030-24424-5
024 7 $a10.1007/978-3-030-24424-8
035   $a(CKB)4100000009273696
035   $a(DE-He213)978-3-030-24424-8
035   $a(MiAaPQ)EBC5896872
035   $a(iGPub)SPNA0062391
035   $a(PPN)260304301
035   $a(EXLCZ)994100000009273696
100   $a20190913d2019      u|         0
101 0 $aeng
135   $aurnn#008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aResistance to Targeted Therapies in Lymphomas /$fedited by Ana C. Xavier, Mitchell S. Cairo
205   $a1st ed. 2019.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2019.
215   $a1 online resource (XX, 210 p. 27 illus., 26 illus. in color.)
225 1 $aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v21
300   $aIncludes index.
311   $a3-030-24423-7 
327   $aMechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies -- Resistance to Monoclonal Antibody Therapeutics in Lymphoma -- Resistance to Antibody-Drug Conjugate -- Resistance to Proteasome Inhibitor Therapy in Non-Hodgkin Lymphoma -- Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma -- Resistance to Bruton?s Tyrosine Kinase Signaling Pathway Targeted Therapies -- Resistance to Checkpoint Blockade Inhibitors and Immunomodulatory Drugs -- Resistance to Bispecific T-cell Engagers and Bispecific Antibodies -- Resistance to Chimeric antigen receptor T-cell therapy -- Index.
330   $aThis volume will review different classes of "target" drugs that have been developed, approved, or are under investigation in the field of lymphoma therapy. The discussion will not only be on the understanding of the mechanisms of action or clinical response of those agents, but also help the reader to understand the nature of lymphoma biology in patients who relapse or are refractor after exposure to those drugs. Contributors will discuss what is currently known about mechanisms of tumor-related or host-related resistance, and how to overcome this resistance. This understanding is crucial given the dismal outcomes of patients with relapsed or refractory lymphomas. The book provides a unique opportunity to review and reflect on the recent successes and pitfalls of the modern lymphoma therapy era. .
410  0$aResistance to Targeted Anti-Cancer Therapeutics,$x2196-5501 ;$v21
606   $aLymphomas$xTreatment
606   $aDrug resistance
606   $aLymphoma$xtherapy
606   $aMolecular Targeted Therapy
606   $aDrug Resistance, Neoplasm
615  0$aLymphomas$xTreatment.
615  0$aDrug resistance.
615 12$aLymphoma$xtherapy.
615 22$aMolecular Targeted Therapy.
615 22$aDrug Resistance, Neoplasm.
676   $a614.5999
676   $a616.99446
702   $aXavier$b Ana C
702   $aCairo$b Mitchell S
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910349443803321
996   $aResistance to Targeted Therapies in Lymphomas$92022549
997   $aUNINA